"Mortalita u schizofrenie je dvojn\u00E1sobn\u00E1 oproti b\u011B\u017En\u00E9 populaci. Polovina t\u011Bchto \u00FAmrt\u00ED je p\u0159ipisov\u00E1na kardiovaskul\u00E1rn\u00EDm p\u0159\u00ED\u010Din\u00E1m. Hlavn\u00EDm c\u00EDlem prevence je sn\u00ED\u017Een\u00ED hladiny LDL cholesterolu. Doporu\u010Duje se l\u00E9\u010Dba statiny a zm\u011Bna \u017Eivotn\u00EDho stylu. Do studie vstoupilo 100 pacient\u016F se schizofreni\u00ED a t\u011B\u017Ekou dyslipidemi\u00ED. V\u0161ichni u\u017E\u00EDvali antipsychotika. 52 nemocn\u00FDch u\u017E\u00EDvalo rosuvastatin, ostatn\u00EDm \u017E\u00E1dn\u00FD statin nebyl ordinov\u00E1n. Po t\u0159ech m\u011Bs\u00EDc\u00EDch byl hodnocen \u00FA\u010Dinek hypolipidemika na lipidov\u00FD profil, gluk\u00F3zovou homeost\u00E1zu a slo\u017Eky metabolick\u00E9ho syndromu. Studie za\u010Dala v roce 2003. Nyn\u00ED jsou uvedena data, dostupn\u00E1 do prosince 2005. Po t\u0159\u00EDm\u011Bs\u00ED\u010Dn\u00ED l\u00E9\u010Db\u011B statinem byl pozorov\u00E1n v\u00FDrazn\u00FD pokles triglycerid\u016F, celkov\u00E9ho cholesterolu, LDL cholesterolu a non-HDL cholesterolu. Rozd\u00EDl oproti pacient\u016Fm bez l\u00E9\u010Dby statinem byl vysoce statisticky v\u00FDznamn\u00FD. Nebyl prok\u00E1z\u00E1n \u00FA\u010Dinek statinu na HDL cholesterol, body mass index, obvod pasu nebo gluk\u00F3zovou homeost\u00E1zu. Statin v\u0161ak ovlivnil s\u00E9rovou hladinu triglycerid\u016F. Rosuvastatin se uk\u00E1za"@cs . "11150" . "L\u00E9\u010Dba z\u00E1va\u017En\u00E9 dyslipidemie rosuvastatinem u schizofrenie a schizoafektivn\u00ED poruchy"@cs . . . "504342" . "12" . "0160-6689" . . . . "8"^^ . "RIV/00216208:11150/06:00004385!RIV07-MSM-11150___" . "dyslipidemia; rosuvastatin; schizophrenia; schizoaffective disorder"@en . . "Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder"@en . "Z(MSM0021620816)" . . "L\u00E9\u010Dba z\u00E1va\u017En\u00E9 dyslipidemie rosuvastatinem u schizofrenie a schizoafektivn\u00ED poruchy"@cs . "67" . . "Mortality rates in patients with schizophrenia are double compared to those in the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density lipoprotein (LDL) cholesterol is recognized as a primary target for the prevention of cardiovascular mortality according to the National Cholesterol Education Program-Adult Treatment Panel III. Use of lipid-lowering drugs such as statins is recommended when lifestyle changes are not sufficient to reach the LDL goal. The efficacy and safety of rosuvastatin treatment were evaluated in schizophrenic patients. 100 schizophrenic patients with severe dyslipidemia were identified. All were treated with antipsychotics. Fifty-two patients were treated with rosuvastatin and compared with 48 who did not receive statin treatment. All patients were screened for cardiovascular risk factors and examined at baseline. The effects of lipid-lowering medication on lipid profile, glucose homeostasis, and components of metabolic syndrome were eval" . . . . "Journal of Clinical Psychiatry" . "RIV/00216208:11150/06:00004385" . . "Mortality rates in patients with schizophrenia are double compared to those in the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density lipoprotein (LDL) cholesterol is recognized as a primary target for the prevention of cardiovascular mortality according to the National Cholesterol Education Program-Adult Treatment Panel III. Use of lipid-lowering drugs such as statins is recommended when lifestyle changes are not sufficient to reach the LDL goal. The efficacy and safety of rosuvastatin treatment were evaluated in schizophrenic patients. 100 schizophrenic patients with severe dyslipidemia were identified. All were treated with antipsychotics. Fifty-two patients were treated with rosuvastatin and compared with 48 who did not receive statin treatment. All patients were screened for cardiovascular risk factors and examined at baseline. The effects of lipid-lowering medication on lipid profile, glucose homeostasis, and components of metabolic syndrome were eval"@en . "1889;1896" . "Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . "1"^^ . "[9BCDD7454F39]" . . "Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder" . . "Kalnick\u00E1, Dita" . "8"^^ . "Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder"@en . .